Treatment with either specific IL-6 antibody or a specific pSTAT3 inhibitor (LLL12), leads to a reduced colony-forming capacity of the stem-like cells from a high-grade clinical prostate cancer sample. The gene discussed is IL6; the disease is prostate carcinoma.